Introduction
The proliferating cell nuclear antigen, PCNA, is an auxiliary factor for DNA polymerase processivity. PCNA interacts with numerous DNA replication/repair enzymes, such as DNA polymerase delta and epsilon, replication factor C (RF-C p140), DNA ligase 1, replication endonuclease FEN-1, Uracil-DNA glycosylase 2, MLH1, MSH2 and the DNA repair endonuclease, XPG (Chuang et al., 1997; Loor et al., 1997; Umar et al., 1996) . Most of these enzymes do not recognize DNA sequences with high speci®city. PCNA binds to double strand DNA as a homotrimer and serves as a platform to tether polymerases to the DNA template during DNA synthesis (Kelman and Hurwitz, 1998) . PCNA has been shown to interact with DNA (cytosine-5) methyltransferase (MCMT) in post-replication DNA synthesis. MCMT methylation of newly synthesized DNA regulates chromatin organization and gene expression.
Several non-enzymatic cell cycle regulators, such as CDK inhibitors p21 CIP/WAFI (Xiong et al., 1992; FloresRozas et al., 1994; Waga et al., 1994) , p57 Kip2 (Watanabe et al., 1998), and Gadd45 (Smith et al., 1994; Hall et al., 1995; Sanchez and Elledge, 1995) , also bind to PCNA. p21 and p57 both contain two separate binding activities: a CDK-cyclin binding domain at the N-terminus and a C-terminally located PCNA binding site (Watanabe et al., 1998; Luo et al., 1995; Nakanishi et al., 1995) , both of which are capable of inhibiting cell cycle progression. Mutagenesis and p21-PCNA crystal structure analysis have identi®ed a short amino acid motif (   144   QTSMTDFY   151   in human p21 and   268   SGPLISDFF 276 in human p57) critical for binding to PCNA. In particular, the hydrophobic Met/Leu and Phe residue (underlined), are required for p21 and p57 to bind PCNA at high anities (Watanabe et al., 1998; Warbrick et al., 1995; Gulbis et al., 1996) . In addition to these two CDK inhibitors, a similar conserved PCNA binding motif (also named PIP-box) containing QXXL/I/MXXF/Y (Warbrick, 1998) , is also found in several other PCNA interacting proteins, including xeroderma pigmentosum group G (XPG; Ludwig et al., 1997) ,¯ap endonuclease (FEN-1; Li et al., 1995) and DNA-(cytosine-5) methyltransferase (MCMT; Chuang et al., 1997) . The p21-PCNA association does not aect the overall structure of PCNA or the PCNA-DNA association (Gulbis et al., 1996) . Instead, p21 is capable of competing with these PCNA-binding proteins, potentially preventing PCNA from binding to DNA polymerase and other replication factors. In this study, we identi®ed a novel 15 kD PCNA-associated factor, p15 PAF . p15
PAF contains the conserved PCNA binding motif in which a mutation disrupts PAF ± PCNA binding. Unlike p21 and p57, overexpression of p15 PAF does not inhibit cell cycle progression. Of potential signi®cance, the expression of p15 PAF is substantially elevated in several types of tumors. We suggest that p15 PAF may be a new member of PCNA associated cell proliferation family of regulators.
Results

Identification of p15
PAF A large number of proteins have been identi®ed through binding to PCNA. To clone less abundant PCNA associated proteins, we constructed a yeast twohybrid cDNA library from mixed human tissues of adult whole brain, fetal whole brain, thalamus, and hippocampus at 1 : 1 : 1 : 1 ratio instead of using only whole brain mRNA. This library contains 36 million independent clones. Twenty million transformants were screened. A total of 73 positive clones were identi®ed, including three known PCNA binding proteins (p21, FEN-1, and Uracil-DNA glycosylase 2), validating the authenticity and eciency of the screen. Five of the 73 PCNA-interacting clones contained cDNA inserts corresponding to the expressed sequence tag (EST) clone KIAA0101 deposited in GenBank (Nagase et al., 1995) (Figure 1a ). These ®ve positive clones all contain the PCNA binding motif and encode the entire coding region of KIAA0101. KIAA0101 (D14657) was conceptually translated but is functionally uncharacterized. Due to its PCNA-binding activity, we have therefore named KIAA0101 as PAF (PCNA associated factor). Notably, PAF contains sequence closely related to the PCNA-binding motif present in other PCNAinteracting proteins (Warbrick, 1998) (Figure 1b ). In particular, three highly conserved residues, Gln, Met/ Ile/Leu and Phe, are all conserved in PAF, suggesting that PAF may bind to PCNA in a similar manner as other PCNA binding proteins. PAF competes with p21 for binding to PCNA p21 has been shown to compete with DNA polymerase and FEN-1 for binding to PCNA. Since both p15 PAF and p21 share the same PCNA-binding motif, we tested whether p15 PAF can compete with p21 for binding to PCNA. HA-tagged p15 PAF was co-transfected with Flagtagged p21 into 293 cells, and p15 PAF binding to PCNA was diminished in the presence of increasing concentration of p21 (Figure 2b , upper panels). When Flag-tagged p21 was co-transfected with GFP or HA-tagged p15 PAF into 293 cells, p21's binding to PCNA was also inhibited by increasing the amount of p15 PAF (Figure 2b , lower panels). Results from HA-tagged p15 PAF co-transfection are not shown. Since only very high levels of p15 PAF (6 : 1 ratio) are able to compete with p21 for PCNA association, it is speculated that the anity of p15 PAF to PCNA may be weaker than that p21, although endogenous levels of p21 and p15 PAF were not measured in transfection experiments.
Tissue-specific expression and nuclear localization of PAF PAF gene was expressed as a 1.1 kb message that accumulated in liver, pancreas and planceta at a high levels (Figure 3 ). PAF expression was not detected in heart or whole adult brain, despite the initial isolation from a brain cDNA library. To determine the subcellular localization, we fused full length PAF to the C-terminal of GFP and expressed PAF ± GFP protein in Hela cells by transient transfection. As shown in Figure 4 , the majority of green¯uorescence was observed in the nucleus, although some cytoplasmic distribution can also be seen. Hence, PAF is mainly localized to the nucleus.
p15
PAF expression is increased in tumor tissues PCNA expression has been correlated to tumor progression and is commonly used as a molecular marker for detecting hyperplastic cell growth. Increased p21 expression has also been seen in several types of malignant tumors (Baekelandt et al., 1999; Barboule et al., 1998) , and a higher level of p21 has been correlated with higher 5-year survival rate (Kuwahara et al., 1999; Natsugoe et al., 1999; Ropponen et al., 1999) . To evaluate p15
PAF 's potential function in tumor development, p15 PAF expression level was measured using tumor blots (Invitrogen). As shown in Figure 5 , the p15 PAF mRNA level was signi®cantly increased in esophageal, breast, uterine, cervix, brain, kidney and lung tumors. This increased mRNA level is especially dramatic in esophageal tumor (410-fold). Northern analysis also veri®ed that in normal whole adult brain tissue, little or no p15 PAF was detected. Little or an undetectable change of p15 PAF expression was observed in colorectal cancer or pancreas tumor.
Discussion
Both PCNA and p21 have been shown to interact with a large number of cellular proteins involved in DNA replication/repair and cell cycle control. Most of the nonenzymatic PCNA binding proteins identi®ed, such as p21 and p57, inhibit DNA synthesis and cell cycle progression. Since p15 PAF is able to compete with p21 for binding to PCNA, it is plausible to speculate that over-expression of p15 PAF in tumor tissues may be advantageous for tumor cell proliferation. However, co-transfection of p15 PAF with p21 expression plasmid into Saos-2 and 293 cells did not show a signi®cant change in p21 induced cell cycle arrest. In addition, PCNA has more than one p21/ p15 PAF binding site and may bind to both p15 PAF and p21 Figure 1 p15 PAF was identi®ed in a yeast two-hybrid screen using PCNA as the bait. (a) Cloning of p15 PAF by binding to PCNA Yeast Y190 cells were simultaneously transformed with a plasmid expressing a GAL4 bd fusion protein and a plasmid expressing a GAL4 ad fusion protein as indicated. Cells were streaked on non-selective medium with histidine (7Leu, 7Trp), selective medium without histidine (7Leu, 7Trp, 7His) and selective medium without histidine but containing 5 mM 3-amino-1,2,3-triazole (7Leu, 7Trp, 7His, 3-AT). Staining for b-galactosidase expression, activated from an independent GAL4 responsive promoter, is shown lower right panel (denoted by b-gal). The C-terminal domain of p21 possesses a trans-activating activity (self-activation) when expressed as fusion protein with the GAL4 DNA binding domain. (data not shown). This result excludes the possibility that a dysfunctional copy of p15 PAF is over-expressed in tumor tissues. Increased expression of p15 PAF in many tumor tissues is not surprising. Expression of PCNA and PCNA-associated proteins such as p21 is also increased in several types of cancers including ovarian cancer and breast cancer. The inhibitory eect of p21 may be overcome by coordinated accumulation of PCNA, cyclinD1 and CDKs (Russell et al., 1999) . Similarly, the impact of increased expression of p15 PAF in tumor tissues may be neutralized by elevated expression of its binding partners, such as PCNA. However, elevated levels of p15 PAF in tumor tissues may be a useful prognostic parameter for certain types of cancer. In esophageal squamous cell carcinoma patients, for example, the 5-year survival rate of p21 positive patients is better than that of p21 negative patients. In other types of cancer, p21's value as an independent prognostic marker is not conclusive. Since p15 PAF expression in esophageal tumor is dramatically elevated compared with normal tissue, the possibility exists that p15 PAF levels could be used to predict clinical prognosis for esophageal cancer patients. PAF is indicated by arrow. b-actin is used as control. The DNA probe of p15 PAF was 32 P labeled using an Ambion kit (#1455). Kodak X-ray ®lm was exposed for 24 h after hybridization Oncogene p15 PAF , a novel PCNA associated factor P Yu et al
Materials and methods
Yeast two-hybrid screening
For yeast two-hybrid screening (Fields and Song, 1989) , full length PCNA was used as bait to screen a human brain cDNA library constructed from mixed mRNA of whole adult brain, whole fetal brain, hippocampus, and thalamus. OligodT primer was used to make a unidirectional cDNA library and was ligated into XhoI ± EcoRI sites of the pACT2 vector. Random hexamers were used to construct a second bidirectional library and was ligated into the EcoRI site of pACT2. The combined cDNA library represents 36 million independent clones. Yeast strain Y190 was used and 20 million transformants were screened on SD-LWH+3AT (45 mM) plates from a single round of screening.
Transfection and immunoprecipitation
The Ca 2+ phosphate method was used in all transfection experiments. 2610 6 Phoenix-A (293 T) cells were harvested 24 h after the transfection of HA-p15PAF (5 mg) and lysed in 0.5 ml lysis buer (50 mM HEPES [7.6], 250 mM NaCl, 0.1% NP-40, 5 mM EDTA). The immunoprecipitated proteins were prepared by incubating the anti-HA monoclonal Ab with the cell lysates. Volumes were adjusted by normalization with expression of Flag-tagged or HA-tagged proteins analysed by Western blot analysis (protein levels before adjustment for IP shown in middle and bottom panels of Figure 2 ). The anti-HA immunoprecipitated samples were then washed three times with high stringency lysis buer (1% NP-40 and 1 M NaCl). For each immunoprecipitation following normalization, aliquots of the lysates were incubated with a 1 : 1 slurry of anti-HA conjugated Sepharose (BAbCO). The Sepharose beads were washed once with 1 ml lysis buer and three times with high stringency lysis buer (1 M NaCl, 1% NP-40). The immunoprecipitated proteins or cell lysates were fractionated on a 4 ± 20% gradient SDS ± PAGE gel (Novex).
Cell cycle assay
A549 cells were infected with vector or p15 PAF retrovirus supernatant which were collected from transfected Phoneix A Figure 4 p15 PAF is localized in the nucleus. GFP-tagged control vector and PAF ± GFP were transiently transfected into Hela cells. Twenty-four hours after transfection,¯uorescence was recorded using a Nikon TE300¯uorescence microscope Figure 5 p15 PAF is highly expressed in some tumor tissues. Human tumor tissue panel blots were purchased from Invitrogen (D3100-01, D3200-01, D3400-01). b-actin probe was used as control. 32 P-labeled p15 PAF probe was used and the X-ray ®lm was exposed for 48 h. Tumor tissues with elevated level of p15 PAF , such as breast, uterine tissue, cervix, brain, kidney, lung and esophageal tumors are labeled by * underneath (upper panel 
